

The 1st Korean Immuno-Oncology Symposium

2018년 3월 16일(금) 서울롯데호텔 (소공동) 3층

인사말 최은경 (대한암학회 회장)

09:00 - 09:10

1 Recent trends in cancer immunology 1

09:10 - 10:30

① Iatrogenic immunosuppression in patients with cancer:

Etiology, consequences, and approaches to preserve immune competence

Stuart A. Grossman (Professor of Oncology, Medicine & Neurosurgery, the Johns Hopkins University School of Medicine)

② Treatment related immunosuppression: What do we know and what can we do

Jian Li Campian (Assistant Professor of Medicine, Washington University School of Medicine)

2 Recent trends in cancer immunology 2

10:50 - 12:00

① What happens to CD8+ T cells upon anti-PD-1 therapy?

신의철 (KAIST 의과학대학원)

② IL-7 in mice and humans: Beyond T cell homeostasis

Ronald Eugene Gress (Chief, Experimental Transplantation and Immunology Branch, CCR, NCI)

Satellite Symposium (by MSD)

12:00 - 13:00

Immuno-oncologic strategy for head and neck cancer and urothelial carcinoma

김범석 (서울의대)

3 Development of novel immunotherapeutics 1

13:00 - 14:40

① Targeting TGF- β : A key strategy to overcome resistance to immunotherapy

John J. Letterio (Director, the Angie Fowler Adolescent & Young Adult Cancer Institute,
University Hospitals Rainbow Babies & Children's Hospital, University Hospitals Cleveland Medical Center)

② Development of tissue-agnostic immunotherapy utilizing stromal TBRS (TGF-beta responsive gene signature)

옥찬영 (메드팩토 / 테라젠)

③ Tumor biology-based immunotherapy using vaccine

박경화 (고려의대 중앙혈액내과)

4 Development of novel immunotherapeutics 2

15:00 - 16:50

① Translating science into immuno-oncology therapies

Jingwu Zang (Founder and CEO of I-MAB Biopharma)

② A new antigen presenting cell based cancer therapeutic vaccine

강창울 (서울대 약학대학)

③ Drivers in the clinical development of cancer combination therapy

Emmett Vance Schmidt (Distinguished Scientist/Executive Director, Clinical Oncology, Merck Research Laboratories)